Beijing Science Sun Pharmaceutical Co., Ltd. (SHE:300485)
China · Delayed Price · Currency is CNY 9.63
-0.41 (-4.08%)
May 20, 2026, 2:35 PM CST
SHE:300485 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 396.22 | 398.32 | 414.95 | 475.92 | 733.73 | 1,050 |
Other Revenue | 6.4 | 6.4 | 1.53 | 0.65 | 0.82 | 1.15 |
| 402.62 | 404.72 | 416.48 | 476.57 | 734.55 | 1,051 | |
Revenue Growth (YoY) | 0.78% | -2.82% | -12.61% | -35.12% | -30.10% | -3.97% |
Cost of Revenue | 141.47 | 147.59 | 143.23 | 140.94 | 171.61 | 182.12 |
Gross Profit | 261.15 | 257.13 | 273.26 | 335.63 | 562.94 | 868.68 |
Selling, General & Admin | 198.74 | 197.43 | 199.12 | 292.63 | 429.92 | 658.62 |
Research & Development | 65.95 | 69.51 | 46.22 | 77.73 | 100.63 | 103.84 |
Other Operating Expenses | 8.05 | 8.33 | 6.65 | 6.61 | 8.76 | 11.74 |
Operating Expenses | 271.85 | 274.38 | 250.81 | 375.38 | 538.7 | 773.27 |
Operating Income | -10.7 | -17.25 | 22.44 | -39.75 | 24.24 | 95.41 |
Interest Expense | -0.45 | -0.45 | - | - | - | - |
Interest & Investment Income | 15.35 | 29.55 | 1.71 | 60.91 | 87.19 | 144.34 |
Currency Exchange Gain (Loss) | 0.35 | 0.35 | 0 | 0 | -0 | -0 |
Other Non Operating Income (Expenses) | 3.02 | -0.03 | 0.25 | -0.05 | -0.33 | -0.26 |
EBT Excluding Unusual Items | 7.56 | 12.18 | 24.4 | 21.11 | 111.1 | 239.49 |
Gain (Loss) on Sale of Investments | -29.84 | 8.61 | -108.13 | 100.27 | 125.41 | 185.65 |
Gain (Loss) on Sale of Assets | 0.11 | 0.11 | - | 0 | 6.65 | 6.57 |
Asset Writedown | -11.38 | -11.38 | - | - | -0.04 | -0 |
Other Unusual Items | 2.75 | 2.75 | 0.1 | 0.74 | 11.43 | 7.2 |
Pretax Income | -30.76 | 12.3 | -83.57 | 122.16 | 254.62 | 439.02 |
Income Tax Expense | -3.42 | 4.51 | -6.69 | 25.76 | 51.97 | 43.89 |
Earnings From Continuing Operations | -27.34 | 7.79 | -76.87 | 96.41 | 202.65 | 395.13 |
Minority Interest in Earnings | 6.6 | 6.78 | 8.02 | 6.51 | 2.09 | 7.14 |
Net Income | -20.74 | 14.57 | -68.85 | 102.92 | 204.73 | 402.27 |
Net Income to Common | -20.74 | 14.57 | -68.85 | 102.92 | 204.73 | 402.27 |
Net Income Growth | - | - | - | -49.73% | -49.10% | 159.69% |
Shares Outstanding (Basic) | 485 | 486 | 492 | 490 | 476 | 479 |
Shares Outstanding (Diluted) | 485 | 486 | 492 | 490 | 476 | 479 |
Shares Change (YoY) | -1.28% | -1.24% | 0.35% | 2.93% | -0.58% | -1.07% |
EPS (Basic) | -0.04 | 0.03 | -0.14 | 0.21 | 0.43 | 0.84 |
EPS (Diluted) | -0.04 | 0.03 | -0.14 | 0.21 | 0.43 | 0.84 |
EPS Growth | - | - | - | -51.16% | -48.81% | 162.50% |
Free Cash Flow | -72.09 | -73.2 | 34.85 | -31.7 | 67.15 | 137.38 |
Free Cash Flow Per Share | -0.15 | -0.15 | 0.07 | -0.07 | 0.14 | 0.29 |
Dividend Per Share | 0.300 | 0.300 | - | 0.022 | 0.086 | 0.168 |
Dividend Growth | - | - | - | -74.42% | -48.81% | 158.46% |
Gross Margin | 64.86% | 63.53% | 65.61% | 70.43% | 76.64% | 82.67% |
Operating Margin | -2.66% | -4.26% | 5.39% | -8.34% | 3.30% | 9.08% |
Profit Margin | -5.15% | 3.60% | -16.53% | 21.60% | 27.87% | 38.28% |
Free Cash Flow Margin | -17.90% | -18.09% | 8.37% | -6.65% | 9.14% | 13.07% |
EBITDA | 36.2 | 29.66 | 69.34 | 8.64 | 71.64 | 151.09 |
EBITDA Margin | 8.99% | 7.33% | 16.65% | 1.81% | 9.75% | 14.38% |
D&A For EBITDA | 46.9 | 46.9 | 46.9 | 48.39 | 47.39 | 55.68 |
EBIT | -10.7 | -17.25 | 22.44 | -39.75 | 24.24 | 95.41 |
EBIT Margin | -2.66% | -4.26% | 5.39% | -8.34% | 3.30% | 9.08% |
Effective Tax Rate | - | 36.69% | - | 21.08% | 20.41% | 10.00% |
Revenue as Reported | 404.72 | 404.72 | 416.48 | 476.57 | 734.55 | 1,051 |
Advertising Expenses | - | - | - | 2.4 | 137.51 | 293.09 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.